Interferon-β plus ribavirin for patients with hepatitis C virus genotype 1: A randomised pilot trial [10]

Gut

Volumn 55, Issue 1, 2006, Pages 139-140

  Enomoto, M ^a   Tamori, A ^a   Kawada, N ^a   Jomura, H ^a   Nishiguchi, S ^b   Saibara, T ^c   Onishi, S ^c   Mochida, S ^d   Fujiwara, K ^d  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BETA INTERFERON; RIBAVIRIN;

ANEMIA; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; TIME SERIES ANALYSIS;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON-BETA; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 29244436884     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.081935     Document Type: Letter

References (5)

1. Dusheiko G, Barnes E, Webster G, et al. The science, economics, and effectiveness of combination therapy for hepatitis C. Gut 2000;47:159-61.
2. Kakumu S, Yoshioka K, Wakita T, et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993;105:507-12.
3. Domanski P, Nadeau OW, Platanias LC, et al. Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J Biol Chem 1998;273:3144-7.
4. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998;95:15623-8.
5. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36(suppl 1):S145-51.